Empowered Funds’s Cytokinetics CYTK Stock Holding History

Empowered Funds’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,237	Closed	-$269K	–	2129
2025 Q4	$269K	Sell	4,237 -106	-2%	-$6.59K	﹤0.01%	885
2025 Q3	$239K	Buy	+4,343	New	+$179K	﹤0.01%	1662
2022 Q3	–	Sell	-53,146	Closed	-$2.09M	–	333
2022 Q2	$2.09M	Buy	+53,146	New	+$2.14M	0.27%	106

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empowered Funds's CYTK Position: Q1 2026 in Review

Empowered Funds sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 4,237 shares — an estimated $269K sold.

Empowered Funds first reported a position in CYTK in Q2 2022 and held it in 3 quarters. The position peaked at $2.09M in Q2 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Empowered Funds reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Empowered Funds sold 4,237 Cytokinetics shares in Q1 2026, an estimated $269K.
Empowered Funds first reported a position in Cytokinetics in Q2 2022 and held it in 3 quarters.
Empowered Funds's Cytokinetics position peaked at $2.09M in Q2 2022.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.